250 related articles for article (PubMed ID: 9740503)
1. Postprandial hyperglycaemia and alpha-glucosidase inhibitors.
Baron AD
Diabetes Res Clin Pract; 1998 Jul; 40 Suppl():S51-5. PubMed ID: 9740503
[TBL] [Abstract][Full Text] [Related]
2. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
Sjöholm A
Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972
[TBL] [Abstract][Full Text] [Related]
3. [Postprandial hyperglycemia. Postprandial blood glucose fluctuations, cardiovascular disease and late diabetic complications].
Madsbad S; Brock B; Schmitz O
Ugeskr Laeger; 2003 Aug; 165(33):3149-53. PubMed ID: 12968409
[TBL] [Abstract][Full Text] [Related]
4. What does postprandial hyperglycaemia mean?
Heine RJ; Balkau B; Ceriello A; Del Prato S; Horton ES; Taskinen MR
Diabet Med; 2004 Mar; 21(3):208-13. PubMed ID: 15008828
[TBL] [Abstract][Full Text] [Related]
5. Drug therapy of postprandial hyperglycaemia.
Mooradian AD; Thurman JE
Drugs; 1999 Jan; 57(1):19-29. PubMed ID: 9951949
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
7. Postprandial and basal hyperglycaemia in type 2 diabetes: Contributions to overall glucose exposure and diabetic complications.
Monnier L; Colette C
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S9-6S15. PubMed ID: 26774019
[TBL] [Abstract][Full Text] [Related]
8. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
Charpentier G; Riveline JP; Dardari D; Varroud-Vial M
Drugs; 2006; 66(3):273-86. PubMed ID: 16526817
[TBL] [Abstract][Full Text] [Related]
9. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
10. The importance of postprandial hyperglycaemia in development of cardiovascular disease in people with diabetes: point.
Haffner S
Int J Clin Pract Suppl; 2001 Sep; (123):24-6. PubMed ID: 11594293
[No Abstract] [Full Text] [Related]
11. Postprandial hyperglycaemia and vascular damage--the benefits of acarbose.
Båvenholm PN; Efendic S
Diab Vasc Dis Res; 2006 Sep; 3(2):72-9. PubMed ID: 17058626
[TBL] [Abstract][Full Text] [Related]
12. The importance of postprandial hyperglycaemia in development of cardiovascular disease in people with diabetes: counterpoint.
Heine RJ
Int J Clin Pract Suppl; 2001 Sep; (123):27-9. PubMed ID: 11594294
[No Abstract] [Full Text] [Related]
13. [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].
Ampudia-Blasco FJ; Ceriello A
Med Clin (Barc); 2010 Sep; 135 Suppl 2():33-9. PubMed ID: 21420536
[TBL] [Abstract][Full Text] [Related]
14. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
16. Postprandial hyperglycaemia in type 2 diabetes: pathophysiological aspects, teleological notions and flags for clinical practice.
Boutati EI; Raptis SA
Diabetes Metab Res Rev; 2004; 20 Suppl 2():S13-23. PubMed ID: 15551342
[TBL] [Abstract][Full Text] [Related]
17. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications.
Ceriello A
Diabetologia; 2003 Mar; 46 Suppl 1():M9-16. PubMed ID: 12652353
[TBL] [Abstract][Full Text] [Related]
18. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.
Bonora E; Muggeo M
Diabetologia; 2001 Dec; 44(12):2107-14. PubMed ID: 11793012
[TBL] [Abstract][Full Text] [Related]
19. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states.
Holman RR
Diabetes Res Clin Pract; 1998 Jul; 40 Suppl():S21-5. PubMed ID: 9740498
[TBL] [Abstract][Full Text] [Related]
20. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes.
Tushuizen ME; Diamant M; Heine RJ
Postgrad Med J; 2005 Jan; 81(951):1-6. PubMed ID: 15640422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
